Cargando…

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients

Detalles Bibliográficos
Autores principales:	Ivanova, Svetlana, Boiko, Anastasia, Bokhan, Nikolay, Fedorenko, Olga, Freidin, Maxim, Loonen, Anton, Osmanova, Diana, Pozhidaev, Ivan, Semke, Arkadiy, Wilffert, Bob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616448/ http://dx.doi.org/10.1093/ijnp/pyw041.515

Ejemplares similares

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
por: Fedorenko, Olga Yu., et al.
Publicado: (2020)

Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia
por: Geers, Lisanne M., et al.
Publicado: (2020)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
por: Ivanova, Svetlana A, et al.
Publicado: (2016)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2023)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2022)

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
por: Mednova, Irina A., et al.
Publicado: (2022)

Management of antipsychotic-induced hyperprolactinemia
por: Tewksbury, Ashley, et al.
Publicado: (2016)

PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)

The effect of antipsychotic medication and the associated hyperprolactinemia as a risk factor for periodontal diseases in schizophrenic patients: a cohort retrospective study
por: Shalaby, Rania, et al.
Publicado: (2023)

Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
por: Fedorenko, Olga Yu, et al.
Publicado: (2015)

Hyperprolactinemia with Antipsychotic Drugs in Children and Adolescents
por: Rosenbloom, Arlan L.
Publicado: (2010)

Antipsychotics-induced hyperprolactinemia and screening for macroprolactin
por: Ruljancic, Nedjeljka, et al.
Publicado: (2020)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

Correction: Hyperprolactinemia with antipsychotic drugs in children and adolescents
por: Rosenbloom, Arlan L
Publicado: (2013)

Hyperprolactinemia with antipsychotics and the need for magnetic resonance imaging
por: Molina Liétor, M.D.C., et al.
Publicado: (2022)

Hormonal alterations due to antipsychotic-related hyperprolactinemia
por: Montejo, A.L., et al.
Publicado: (2022)

Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
por: Ochi, Taichi, et al.
Publicado: (2019)

Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
por: Ochi, Taichi, et al.
Publicado: (2021)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Selective serotonin reuptake inhibitor-induced galactorrhea with hyperprolactinemia
por: Bhattacharjee, Subir, et al.
Publicado: (2021)

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
por: Levchenko, Anastasia, et al.
Publicado: (2018)

Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers
por: Ishioka, Masamichi, et al.
Publicado: (2015)

Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia
por: Raveendranthan, Dhanya, et al.
Publicado: (2018)

Hyperprolactinemia and breast enlargement with serotonin reuptake inhibitor and olanzapine combination
por: Praharaj, Samir Kumar
Publicado: (2011)

Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
por: Geers, Lisanne M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hct74j5rebh0fjmajoqli41pu2